All News
SpA: Etiology to Diagnosis to Treatment - An Abstract Roundup
Here's a review of ten abstracts and presentations on spondyloarthritis encompassing a wide range of topics from etiology to diagnosis to treatment.
Read Article
Revisit #ACR20 through our podcast!
Best Practices for APL Testing,
Is COVID19 infection bad for rheumatic disease patients?
Pregnancy in SpA Patients
A New Pathway (Deucravacitinib) in Psoriatic Arthritis
https://t.co/kmoOL4d3oF https://t.co/qQQd1aJm8K
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @doctorRBC : AxSpa pts had Significant Gut Microbiome Differences in:
1⃣Disease activity and duration
2⃣Enthesitis
3⃣Radiographic involvement
Abs#1853 https://t.co/ynemrgsP3W
Dr. John Cush RheumNow ( View Tweet)
Tight Control Tune: Third Verse, Same as the First? TICOSPA. Dr. Jeff Curtis ( @RADoctor) reviews abstract #1444 at #ACR20.
https://t.co/4tqWuzwn54 https://t.co/u0vn4d1yF8
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @uptoTate : Study out of China, #ABS1892 shows that patient reported outcomes using self assessments are important in AS T2T and decreasing flare rates #ACR20 @RheumNow. https://t.co/vWjvAEeDMi https://t.co/HdMKSkkJ8I
Links:
Dr. John Cush RheumNow ( View Tweet)
Missing the Mark: AxSpa Treat to Target (TICOSPA Trial): Dr. Lianne Gensler #ACR20
https://t.co/ePrhQ90kwD
Links:
Dr. John Cush RheumNow ( View Tweet)
Pregnancy in SpA Patients: Dr Rachel Tate ( @uptoTate) #ACR20
https://t.co/GPrwd9HU5W https://t.co/TbwN4dZNul
Links:
Dr. John Cush RheumNow ( View Tweet)
New Treatments in Axial Spondyloarthritis: Dr. Antoni Chan ( @synovialjoints) discuses two abstracts presented at the #ACR20 annual meeting.
https://t.co/bh7l6C8p7P https://t.co/RN60iWCmet
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Conway ( @RichardPAConway) and Dr. Maguire discuss abstract #1323 presented at the #ACR20 on pregnancy in Spondyloarthritis.
https://t.co/YyWOuiq3jn https://t.co/SnodUbKZTx
Links:
Dr. John Cush RheumNow ( View Tweet)
SpA: Etiology to Diagnosis to Treatment - An Abstract Roundup by Dr. Robert Chao ( @doctorRBC) #ACR20
https://t.co/wR0inoR8jp https://t.co/7SFkThkPSr
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @doctorRBC : Gender disparity in Ankylosing Spondylitis symptoms.
1⃣Women ⬆️Achilles tendonitis, plantar fasciitis, joint swelling, BASDAI>40, DMARD use
2⃣HLA-B not associated w/ enthesitis
@RheumNow #ACR20 Abs#1872 https://t.co/pBcpuqgq0K https://t.co/YWKFUdIgMl
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : #ACR20 Abs#L11. Efficacy of TOFA vs PBO in AS. At week 16, %ASAS20 responders 56% v 29% PBO; %ASAS40 40% vs 12%. @RheumNow #ACRBest https://t.co/knduk3l6xV https://t.co/SNommxn1jA
Links:
Dr. John Cush RheumNow ( View Tweet)
Nomenclature, Uveitis and Other Spondyloarthritis Features with Dr. Lianne Gensler #ACR20
https://t.co/zql7iySXOA https://t.co/PY9k108QTc
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @synovialjoints : Can we find Axial Spa (FaxSpa) using social media? This study used an online screening tool (A-tool) on social media in patients with back pain. 42% had a positive screen and referred for review @RheumNow #ACR20 Abstr#1894
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @synovialjoints : The majority of patients with axSpA were able to use an axSpA smartphone app. recording BASDAI, BASFI 2 weekly. Current disease activity influence adherence to reporting @RheumNow #ACR20 Abstr#1890
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @DrPetryna : #ACR20 abs1535 retrospective study of SI MRI reveals 20% pts w/out spondyloarthritis have BME on an MRI, predominantly in the antero-middle quadrant. Erosions were seen in 31% of healthy patients and in 61% of patients with spondyloarthritis
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @Janetbirdope : Filgo decreased MRI inflammation of many structures early in Rx in SpA which seems novel says w Maksymowych 5M015 @RheumNow #ACR20 @CRASCRRheum #ACRbest https://t.co/5HQiIettjh https://t.co/NwFMkLIhWw
Links:
Dr. John Cush RheumNow ( View Tweet)
Check out of video by Dr. Rachel Tate ( @uptoTate ) titled "Treat to Target in Spondyloarthritis". #ACR20
https://t.co/7ThVtmguFI https://t.co/on9m0qtse3
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @synovialjoints : New mode of action treatment in AS. The SELECT-AXIS 1 showed Upadacitinib 15mg od showed sustained efficacy over 1 year @RheumNow #ACR20 Abstr#2023 #ACRbest https://t.co/Auo3AMNTDw
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @KDAO2011 : FDA updates 6/16/20 canakinumab for AOSD 5/29/20 ixekizumab for nr-AxSpa 80 mg q4wks 3/9/20 nintedanib for progressive ILD 1/29/20 and 6/16/20 secukinumab nr-axSpa 150 mg q4wks, AS 300 mg SQ q4weeks 1/17/20 belimumab label for black pts removed
Dr. John Cush RheumNow ( View Tweet)
